Skip to content

Assessment of VMCore Biopsy Versus Standard of Care Biopsy

A Proof of Concept Assessment of the VMCore Biopsy System for Sampling and Retrieving Prostate Biopsy Cores Compared to a Standard of Care Biopsy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04982536
Enrollment
40
Registered
2021-07-29
Start date
2020-07-19
Completion date
2022-08-01
Last updated
2021-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

Prostate biopsy is the definitive test to establish the diagnosis of prostate cancer. The standard of care biopsy needles do not predictably obtain full cores of tissue and what tissue obtained is often fragmented, making pathologic review a challenge. The VMCore Biopsy System has a geometry in the tip of its biopsy needles that capture more tissue in a single sample. This study is to compare the characteristics of tissue captured by either standard of care needles and the VMCore needle.

Detailed description

This post-market study is being conducted in order to assess the capability of the VMCore biopsy needle to capture prostate tissue in subjects consenting to the use of both the VMCore needle and the urological practice's standard of care needle for twinned samples during a routine prostate biopsy procedure. The primary endpoints are to success in tissue core sampling, safety of the sampling, and subject's tolerance to the procedure.

Interventions

DEVICEStandard of Care Biopsy Needle

Prostate Examine

DEVICEVMCore Biopsy System

Prostate Examine

Sponsors

Uro-1 Medical
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Each subject will have biopsy performed with both the study needle and a standard of care needle

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male * Scheduled for a prostate biopsy * Able and willing to provide verbal assessment of his condition 5 days post-procedure

Exclusion criteria

* Unable or unwilling to provide consent

Design outcomes

Primary

MeasureTime frameDescription
Procedure Success1 Day of the procedurePercentage of tissue samples suitable for pathological review
Adverse Events1 Day of the procedureIncidence and Severity of Adverse events associated with use of the biopsy needles
Patient Pain During use of the biopsy needles1 Day of the procedurePain measured with Likert Scale of 1 to 5

Secondary

MeasureTime frameDescription
Mean Tissue volume for each sample taken1 Day of the procedureLength and diameter of tissue samples for cubic centimeters of volume

Countries

United States

Contacts

Primary ContactThomas Lawson, PhD
drthomlawson@gmail.com5102061794
Backup ContactJack Snoke
pjsnoke@uro1medical.com3365750434

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026